Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-4.61 M USD-5.81 M USD-4.69 M USD-3.02 M USD-1.25 M USD-499551 USD-909476 USD-1.01 M USD-542703 USD-520808 USD-366414 USD
Depreciation & Amortization4.78 M USD4.80 M USD4.87 M USD4.83 M USD2.04 M USD14698 USD22241 USD56194 USD39990 USD25956 USD19772 USD
Stock-Based Compensation1.73 M USD3.54 M USD1.11 M USD6.42 M USD160978 USD150440 USD0 USD100366 USD106250 USD
Capital Expenditures34561 USD21331 USD92984 USD633823 USD143792 USD0 USD1638 USD4908 USD47686 USD7081 USD
Cash Flow from Investing-2223 USD-125292 USD-101525 USD-630178 USD-180517 USD-7243 USD-13107 USD-7277 USD-49096 USD-148330 USD-11578 USD
Cash Flow from Financing1.01 M USD8.03 M USD4.92 M USD3.83 M USD3.15 M USD120000 USD54968 USD254979 USD2.44 M USD782125 USD80574 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-4.65 M USD-5.83 M USD-4.79 M USD-3.66 M USD-1.39 M USD-499551 USD-911114 USD-1.01 M USD-568494 USD-373495 USD

Ainos Inc. is a dual-platform AI and biotech company focused on pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and a smell language model (SLM), digitizes scents into Smell ID, a machine-readable data format that enables intelligent sensing in robotics, smart factories, and healthcare applications. The company develops VELDONA®, a low-dose oral interferon therapy targeting rare, autoimmune, and infectious diseases, with active clinical programs in areas such as HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis. Ainos Inc. also leverages proprietary sensor array technologies to advance healthcare AI and offers point-of-care testing devices, including antigen rapid test kits. These innovations position Ainos Inc. at the intersection of AI-driven diagnostics, scent digitization, and therapeutic solutions, serving medtech needs in diverse healthcare and technology sectors. Incorporated in 1984 and headquartered in the United States, Ainos Inc. continues to redefine machine perception through its integrated AI and biotech capabilities.